Pharmacological management of glycemic control in the geriatric patient with type 2 diabetes mellitus

Consultant Pharmacist

Volumn 24, Issue 1, 2009, Pages 45-63

  Neumiller, Joshua J ^a   Setter, Stephen M ^b   Gates, Brian J ^a   Sonnett, Travis E ^b   Dobbins, Erin K ^a   Campbell, R Keith ^b  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Antihyperglycemics; Diabetes mellitus; Elderly; Geriatrics; Insulin

Indexed keywords

ACARBOSE; ACETOHEXAMIDE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; CHLORPROPAMIDE; DEUTACT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLIBENCLAMIDE PLUS METFORMIN; GLIMEPIRIDE; GLIMEPIRIDE PLUS ROSIGLITAZONE; GLIPIZIDE; GLIPIZIDE PLUS METFORMIN; GLITAZONE DERIVATIVE; HUMALOG MIX; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; MEGLITINIDE; METFORMIN; METFORMIN PLUS PIOGLITAZONE; METFORMIN PLUS ROSIGLITAZONE; MIGLITOL; NATEGLINIDE; PIOGLITAZONE; PRAMLINTIDE; RECOMBINANT HUMAN INSULIN; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; TOLAZAMIDE; TOLBUTAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VILDAGLIPTIN;

ABDOMINAL PAIN; ADVERSE DRUG REACTION; AGED; AGING; ANEMIA; ANOREXIA; BEDTIME DOSAGE; BLOOD DYSCRASIA; BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; DIARRHEA; DISULFIRAM REACTION; DRUG CHOICE; DRUG COST; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG USE; DYSGEUSIA; DYSPEPSIA; EDEMA; FLATULENCE; FLUID RETENTION; FRACTURE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HEADACHE; HEALTH INSURANCE; HEART FAILURE; HEPATITIS A; HUMAN; HYPOGLYCEMIA; LACTIC ACIDOSIS; LIVER FUNCTION TEST; LOW DRUG DOSE; MEGALOBLASTIC ANEMIA; NAUSEA; NOCTURNAL HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSTRUCTIVE JAUNDICE; PERIPHERAL EDEMA; PRACTICE GUIDELINE; RETINA MACULA EDEMA; REVIEW; SIDE EFFECT; TREATMENT PLANNING; VISUAL DISORDER; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 59049091826     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2009.45     Document Type: Review

References (67)

1. Selvin E, Coresh J, Brancati FL. The burden and treatment of diabetes in elderly individuals in the U.S. Diabetes Care 2006;29:2415-9.
2. American Diabetes Association. All about diabetes. Available at http://www.diabetes.org/about-diabetes.jsp. Accessed June 16, 2008.
3. Mathieu C, Bollaerts K. Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors. Int J Clin Pract 2007;61:29-37.
4. Centers for Disease Control and Prevention. National Diabetes Fact Sheet. Available at http://apps.nccd.cdc.gov/DDTSTRS/template/ndfs-2005.pdf. Accessed June 16, 2008.
5. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985;33:278-85.
6. O'Malley K, Crooks J, Duke E et al. Effect of age and sex on human drug metabolism. Br Med J 1971;3:607-9.
7. Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 2004;57:6-14.
8. Turnheim K. Drug therapy in the elderly. Exp Gerentol 2004;39:1731-8.
9. Greenblatt DJ, Harmatz JS, Shader RI. Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly. Therapeutic considerations (Part I). Clin Pharmacokinet 1991 ;21-165-77.
10. Fulop T, Worum I, Csongor J et al. Body composition in elderly people. I. Determination of body composition by multiisotope method and the elimination kinetics of these isotopes in healthy elderly subjects. Gerontology 1985;31:6-14.
11. Campion EW, Avorn J, Reder VA et al. Overmedication of the lowweight elderly. Arch Intern Med 1987;147:945-7.
12. Turnheim K. Drug dosage in the elderly. Is it rational? Drugs Aging 1998;13:357-79.
13. Fick DM, Cooper JW, Wade WE et al. Updating the Beers criteria for potentially inappropriate medication use in older adults. Arch Intern Med 2003;163:2716-24.
14. Graal MB, Wolffenbuttel BH. The use of sulphonylureas in the elderly. DrugsAging 1999;15:471-81.
15. El Desoky ES. Pharmacokinetic-pharmacodynamic crisis in the elderly. Am JTher 2007; 14:488-98.
16. Hsu J, Fung V, Price M et al. Medicare beneficiaries' knowledge of part D prescription drug program benefits and responses to drug costs. JAMA 2008;299:1929-36.
17. Madden JM, Graves AJ, Zhang F et al. Cost-related medication nonadherence and spending on basic needs following implementation of Medicare Part D. JAMA 2008;299:1922-8.
18. American Diabetes Association. Executive summary: standards of medical care in Diabetes 2008 position statement. Diabetes Care 2008;31:56-511.
19. American Diabetes Association. Standards of medical care in diabetes: 2008. Diabetes Care 2008;31:12-54.
20. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-S3.
21. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
22. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9.
23. Brown AF, Mangione CM, Saliba D et al. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc 2003;51: Suppl 5:265-80.
24. Pyörälä K, Pedersen TR, Kuekshus J et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20:614-20.
25. Curb JD, Pressel SL, Cutler JA et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996;276:1886-92.
26. Centers for Medicare and Medicaid. State operations manual appendix PP: guidance to surveyors for long term care facilities. Available at http://www.cms.hhs.gov/manuals/Downloads/som107ap-pp-guidelines-ltcf.pdf. Accessed June 16, 2008.
27. Good CB. Polypharmacy in elderly patients with diabetes. Diabetes Spectrum 2002; 15:240-8.
28. Van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol 1997;50:735-41.
29. Cayea D, Boyd C, Durso SC. Individualising therapy for older adults with diabetes mellitus. Drugs Aging 2007;24:851-63.
30. Hornick T, Aron DC. Managing diabetes in the elderly: go easy, individualize. Cleve Clin J Med 2008;75:70-8.
31. Chelliah A, Burge MR. Hypoglycemia in elderly patients with diabetes mellitus. Drugs Aging 2004;21:511-30.
32. Holstein A, Plaschke A, Egberts EH. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001;17:467-73.
33. Haas L. Management of diabetes mellitus medications in the nursing home. Drugs Aging 2005;22:209-18.
34. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002;137:25-33.
35. Bolen S, Feldman L, Vassy J et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007;147:386-99.
36. Bauman WA, Shaw S, Jayatilleke E et al. Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin. Diabetes Care 2000;23:1227-31.
37. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-18.
38. Nesto RW, Bell D, Bonow RO et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004;27:256-63.
39. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002;287:360-72.
40. US FDA. GlaxoSmithKline letter. Available at http://www.fda.gov/medwatch/ safety/2006/Avandia-DHCPletter.pdf. Accessed June 16, 2008.
41. Schwartz AV, Sellmeyer DE. Effect of thiazolidinediones on skeletal health in women with type 2 diabetes. Expert Opin Drug Saf 2008;7:69-78.
42. Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 2006;60:1454-70.
43. Mathieu C, Bollaerts K. Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors. Int J Clin Pract 2007;61:29-37.
44. American Society of Consultant Pharmacists. Diabetes: Oral Medications Clinical Reference Card. August 2007.
45. Barnett A. Exenatide. Expert Opin Pharmacother 2007;8:2539-608.
46. Odegard PS, Setter SM, Iltz JL. Update in the pharmacologic treatment of diabetes mellitus: focus on pramlintide and exenatide. The Diabetes Educator 2006;32:693-712.
47. Linnebjerg H, Kothare PA, Park S et al. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 2007;64:317-27.
48. Odegard PS, Setter SM, Neumiller JJ. Considerations for the pharmacological treatment of diabetes in older adults. Diabetes Spectrum 2007;20:239-47.
49. Byetta (exenatide) prescribing information. San Diego, CA: Eli Lilly & Co.; 2007.
50. Zinman B, Hoogwerf BJ, Duran Garcia S et al. The effect of adding exenatide to thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007;146:477-85.
51. Kleppinger EL, Vivian EM. Pramlintide for the treatment of diabetes mellitus. Ann Pharmacother 2003;37:1082-9.
52. Borm AK, Klevesath MS, Borcea V et al. The effect of pramlintide (amylin analogue) treatment on bone metabolism and bone density in patients with type 1 diabetes mellitus. Hormone Metab Res 1999;31:472-5.
53. Omnicare, Inc. Geriatric Pharmaceutical Care Guidelines. 2007 ed. Covington, KY: Omnicare, Inc.; 2007.
54. Budnitz DS, Shehab N, Kegler SR et al. Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med 2007;147:755-65.
55. Rosenstock J. Management of type 2 diabetes mellitus in the elderly special considerations. Drugs Aging 2001;18:31-44.
56. Hornick T, Aron DC. Managing diabetes in the elderly: go easy, individualize. Cleve Clin J Med 2008;75:70-8.
57. American Society of Consultant Pharmacists. Diabetes: Injectable and Inhaled Medications. February 2007.
58. Coscelli C, Lostia S, Lunetta M et al. Safety, efficacy, acceptability of a pre-filled insulin pen in diabetic patients over 60 years old. Diabetes Res Clin Pract 1995;28:173-7.
59. Janka HU, Plewe G, Busch K. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus. J Am Geriatr Soc 2007;55:182-8.
60. Riddle MC. Evening insulin strategy. Diabetes Care 1990;13:676-86.
61. Rosenstock J, Schwartz SL, Clark CM et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE901) and NPH insulin. Diabetes Care 2001;24:631-6.
62. Ilte JL, Odegard PS, Setter SM et al. Update in the pharmacologic treatment of diabetes focus on insulin detemir, insulin glulisine, and inhaled dry powdered insulin. Diabetes Educator 2007;33:215-53.
63. Mooradian AD, Bernbaum M, Albert SG. Narrative review: a rational approach to starting insulin therapy. Ann Intern Med 2006;145:125-34.
64. Zarowitz BJ, Tangalos EG, Hollenack K et al. The application of evidence-based principles of care in older persons (issue 3): management of diabetes mellitus. J Am Med Dir Assoc 2006;7:234-40.
65. Coscelli C, Calabrese G, Fedele D et al. Use of premixed insulin among the elderly. Reduction of errors in patient preparation of mixtures. Diabetes Care 1992;15:1628-30.
66. Rolla AR, Rakel RE. Practical approaches to insulin therapy for type 2 diabetes mellitus with premixed insulin analogues. Clin Ther 2005; 27:1113-25.
67. Reza M, Taylor CD, Towse K et al. Insulin improves well-being for selected elderly type 2 diabetic subjects. Diabetes Res Clin Pract 2002;55:201-7.